In an adult with a resistant bacterial lung infection, which antibiotic is preferred: meropenem, ceftazidime‑avibactam, or tigecycline?

Ceftazidime-Avibactam is the Preferred First-Line Agent for Resistant Bacterial Lung Infections

For resistant bacterial lung infections in adults, ceftazidime-avibactam should be your first choice, with meropenem as an alternative when carbapenem resistance is not suspected; tigecycline should be reserved only for specific resistant organisms like CRAB when other options have failed.

Clinical Decision Algorithm

Step 1: Identify the Resistance Pattern

The choice depends critically on which resistance mechanism you're dealing with:

• If carbapenem-resistant Enterobacterales (CRE) or carbapenem-resistant Pseudomonas suspected: Choose ceftazidime-avibactam
• If standard hospital-acquired pneumonia without documented carbapenem resistance: Meropenem remains appropriate per guidelines 1
• If carbapenem-resistant Acinetobacter baumannii (CRAB): Consider tigecycline-based combination therapy 2

Step 2: Apply Evidence-Based Selection

Ceftazidime-avibactam demonstrates superior outcomes in nosocomial pneumonia, including ventilator-associated pneumonia. The REPROVE trial showed non-inferiority to meropenem with 68.8% clinical cure rates in the modified intention-to-treat population 3. Critically, it covers:

• KPC-producing carbapenem-resistant organisms
• OXA-48 carbapenemases
• Difficult-to-treat resistant Pseudomonas aeruginosa
• 28% of isolates were ceftazidime-non-susceptible at baseline yet still responded 3

Meropenem remains guideline-recommended for empiric HAP/VAP treatment when MDRO risk is not established. The 2016 IDSA/ATS guidelines explicitly list meropenem 1g IV q8h as a first-line option for hospital-acquired pneumonia 1. However, its utility diminishes with carbapenem resistance.

Tigecycline has significant limitations for lung infections:

• Shows higher mortality trends compared to polymyxin-based therapy (RR 1.12, though not statistically significant) 2
• Achieves suboptimal lung tissue concentrations
• FDA data shows it's bacteriostatic (not bactericidal) for most organisms 4
• Should be used cautiously in patients with liver insufficiency 2

Critical Resistance Considerations

Metallo-β-Lactamase Producers (NDM, VIM, IMP)

This is where your algorithm changes dramatically:

• Ceftazidime-avibactam ALONE will fail against metallo-β-lactamases
• Combination therapy required: Ceftazidime-avibactam + aztreonam showed 19.2% mortality vs 44% with other agents (HR 0.37,95% CI 0.13-0.74) 2
• Alternative: Consider cefiderocol for MBL-producing strains 5

For KPC-Producing Organisms

Ceftazidime-avibactam is definitively superior to older agents:

• Restores antibacterial activity against KPC-producing CRKP 6
• Higher bacterial clearance rates compared to standard therapy 7
• Lower mortality rates in meta-analyses 7

Practical Implementation

Start with ceftazidime-avibactam 2.5g IV q8h (adjusted for renal function) when:

• Prior antibiotic exposure in last 90 days
• Known local prevalence of carbapenem resistance >10%
• Critically ill patient with septic shock
• Structural lung disease (bronchiectasis, cystic fibrosis)

Use meropenem 1g IV q8h when:

• No recent antibiotic exposure
• Low local carbapenem resistance rates
• Susceptibility confirmed on culture
• Cost considerations in resource-limited settings

Reserve tigecycline (100mg load, then 50mg IV q12h) only for:

• Documented CRAB with MIC ≤2 mg/L 2
• As part of combination therapy, never monotherapy
• When ceftazidime-avibactam and carbapenems have failed

Common Pitfalls to Avoid

1. Don't use tigecycline monotherapy for severe pneumonia—it's associated with treatment failure 2

2. Don't assume ceftazidime-avibactam covers all resistance—it fails against metallo-β-lactamases without aztreonam 2

3. Don't delay obtaining cultures—resistance mechanisms must be identified to optimize therapy 5

4. Monitor for nephrotoxicity with tigecycline alternatives (polymyxins show 225 more nephrotoxicity events per 1000 patients) 2

5. Don't use meropenem empirically in units where carbapenem resistance exceeds 20% among Gram-negatives 1

Safety Profile Comparison

Ceftazidime-avibactam showed 75% adverse event rate vs 74% with meropenem, mostly mild-to-moderate 3. Serious adverse events occurred in 19% vs 13% respectively, with only 4 treatment-related serious events (all in ceftazidime-avibactam group) 3. This favorable profile supports its use as first-line therapy.

The most recent 2023 guidelines on carbapenem-resistant organisms specifically endorse ceftazidime-avibactam for resistant Gram-negative lung infections 2, superseding older recommendations that predate these novel agents. Recent 2026 German guidelines confirm ceftazidime-avibactam as first-choice for MDRO not involving metallo-β-lactamase 5.